Sweetsignal
Pharma commercial strategy
Most pharma strategy decks hand-wave the math.
This is the version that shows it — rare disease targeting, media mix, and the arguments that hold up when you check the numbers.
Who writes it
A Different Kind of Pharma Strategist
sweetsignal is Ted Sweetser’s running argument about where pharma commercial strategy actually works — and where it quietly doesn’t. Rare disease patients misidentified by diagnosis code. Launch plans that underweight their highest-value patients by 50x or more. Media strategy for a world where search engines read for agents, not people. Less deck theater, more arithmetic.
The archive
10
essays, and counting. No gated PDFs, no lead-capture form.
What’s in here
What’s Actually in Here
Recent pieces: why HAE patient targeting breaks when you trust ICD-10 codes, where the real value concentrates in a rare disease population, and what “heavy traffic on a narrow road” means for a launch brand competing in a crowded therapeutic category.
- OCT 29From Blockbuster to Precision: How Drug Launches Change
- OCT 13Adversarial Mechanics and 2nd order consequences for Geo, optimization, pubs: a comparative…
- OCT 7Rare Disease Strategy: Where Value Really Lives in Hereditary Angioedema
- OCT 5What is this jev thing, or, an extended argument on what constitutes a dumpling